Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed ovarian cancer~* Stage IIIB/IV~* Failure to prior chemotherapy with paclitaxel /carboplatin regimen and treatment free interval \> 6 months~* Presence of two-dimensional measurable disease.~* Life expectancy of more than 3 months.~* Age ≥ 18 years.~* Performance status (WHO) 0-2~* Adequate bone marrow function (Absolute neutrophil count \>1000/mm\^3, Platelet count\>100000/mm\^3, Hemoglobin\>9gr/mm\^3)~* Adequate liver (Bilirubin\<1.5 times upper limit of normal and SGOT/SGPT\<2 times upper limit of normal) and renal function (creatinine\<2mg/dl)~* Informed consent~Exclusion Criteria:~* Pregnant or nursing~* Psychiatric illness or social situation that would preclude study compliance'~* Other concurrent uncontrolled illness~* Other invasive malignancy within the past 5 years except nonmelanoma skin cancer~* Other concurrent investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel/carboplatin
- 2 (Type: EXPERIMENTAL): Docetaxel/Caelyx

Based on this trial design, predict the completion outcome and termination type (if applicable).